

TITLE: Preparation of substituted pyrazoles as glucagon receptor antagonists for treating diabetes mellitus type 2

INVENTOR(S): Parmee, Emma; Raghavan, Subharekha; Beeson, Teresa; Shen, Dong-Ming

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 123 pp.  
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069158	A2	20040819	WO 2004-US1927	20040123
WO 2004069158	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210127	A1	20040819	AU 2004-210127	20040123
CA 2513102	A1	20040819	CA 2004-2513102	20040123
EP 1590336	A2	20051102	EP 2004-704951	20040123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516622	T	20060706	JP 2006-502975	20040123
US 20060084681	A1	20060420	US 2005-543290	20050725
PRIORITY APPLN. INFO.:			US 2003-442828P	P 20030127
			WO 2004-US1927	W 20040123
OTHER SOURCE(S):		MARPAT 141:207202		
GI				



AB The title compds. [I; R1 = alkyl, alkenyl, aryl, etc.; R2 = H, R1; R3, R4 = H, alkyl; R5 = H, F; R6 = H, OH, F, alkyl; or R5 and R6 together represent oxo; m = 0-2; n = 0-6; with provisos] which are glucagon receptor antagonists (no data given) and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus, were prepared and formulated. E.g., a 5-step synthesis of II, starting from Me 4-trifluoromethoxybenzoate and acetylcyclohexane, was given.


IT 743432-27-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted pyrazoles as glucagon receptor antagonists for treating diabetes mellitus type 2)

RN 743432-27-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-cyclohexyl-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]-, ethyl ester (CA INDEX NAME)



IT 743432-26-0P 743432-28-2P 743432-29-3P  
 743432-30-6P 743432-32-8P 743432-34-0P  
 743432-36-2P 743432-37-3P 743432-55-5P  
 743432-56-6P 743432-57-7P 743432-58-8P  
 743432-60-2P 743432-63-5P 743432-67-9P  
 743432-75-9P 743432-79-3P 743432-83-9P  
 743432-87-3P 743432-91-9P 743432-95-3P  
 743432-96-4P 743432-97-5P 743433-00-3P  
 743433-01-4P 743433-02-5P 743433-03-6P  
 743433-04-7P 743433-06-9P 743433-09-2P  
 743433-12-7P 743433-14-9P 743433-16-1P  
 743433-19-4P 743433-22-9P 743433-25-6P  
 743433-28-5P 743433-29-6P 743433-30-9P  
 743433-32-1P 743433-35-4P 743433-38-7P  
 743433-40-1P 743433-41-2P 743433-42-3P  
 743433-43-4P 743433-45-6P 743433-47-8P  
 743433-49-0P 743433-51-4P 743433-53-6P  
 743433-55-8P 743433-57-0P 743433-59-2P  
 743433-61-6P 743433-62-7P 743433-64-9P  
 743433-67-2P 743433-68-3P 743433-69-4P  
 743433-70-7P 743433-71-8P 743433-74-1P  
 743433-75-2P 743433-76-3P 743433-77-4P  
 743433-78-5P 743433-79-6P 743433-80-9P  
 743433-81-0P 743433-82-1P 743433-83-2P  
 743433-84-3P 743433-85-4P 743433-86-5P  
 743433-87-6P 743433-89-6P 743433-91-2P


743436-71-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrazoles as glucagon receptor antagonists for treating diabetes mellitus type 2)


RN 743432-26-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-cyclohexyl-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]-, ethyl ester (CA INDEX NAME)




RN 743432-28-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-cyclohexyl-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-29-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-cyclohexyl-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-30-6 CAPLUS

CN Propanoic acid, 3-[[4-[[5-cyclohexyl-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]amino]-2-methyl- (CA INDEX NAME)




RN 743432-32-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[1-cyclohexyl-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-3-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-34-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[1-cyclohexyl-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-5-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-36-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-cyclohexyl-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-37-3 CAPLUS

CN β-Alanine, N-[4-[[3-cyclohexyl-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-55-5 CAPLUS

CN β-Alanine, N-[4-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-56-6 CAPLUS

CN Glycine, N-[4-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-57-7 CAPLUS

CN Butanoic acid, 4-[4-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]amino]- (CA INDEX NAME)



RN 743432-58-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]-N-methyl- (CA INDEX NAME)




RN 743432-60-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[4-(trifluoromethoxy)phenyl]-5-[trans-4-


(trifluoromethyl)cyclohexyl]-1H-pyrazol-1-yl)methyl]benzoyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 743432-63-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl)methyl]benzoyl]- (CA INDEX NAME)




RN 743432-67-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3,5-dichlorophenyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl)methyl]benzoyl]- (CA INDEX NAME)




RN 743432-75-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[1-[3,5-bis(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl]ethyl]benzoyl]- (CA INDEX NAME)




RN 743432-79-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[4-(methylsulfonyl)phenyl]-5-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743432-83-9 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[5-[4-(methylsulfonyl)phenyl]-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)






RN 743432-87-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[1-(4-chlorophenyl)ethyl]-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-91-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[1-(4-chlorophenyl)ethyl]-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-95-3 CAPLUS

CN Glycine, N-[3-[1,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-96-4 CAPLUS

CN  $\beta$ -Alanine, N-[3-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743432-97-5 CAPLUS

CN Butanoic acid, 4-[[3-[[3,5-bis[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]amino]- (CA INDEX NAME)




RN 743433-00-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3'-amino[1,1'-biphenyl]-4-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-01-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(3'-hydroxy[1,1'-biphenyl]-4-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-02-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4-(3,3-dimethyl-1-buten-1-yl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-03-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4'-methyl[1,1'-biphenyl]-4-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-04-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4-(4-pyridinyl)phenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-06-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-09-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3,5-dichlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-12-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-14-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-16-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-19-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3,5-dichlorophenyl)-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-22-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,4-dichlorophenyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-25-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3,4-dichlorophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-28-5 CAPLUS

CN     $\beta$ -Alanine, N-[4-[[3-(2-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-29-6 CAPLUS


CN     $\beta$ -Alanine, N-[4-[[5-(2-pyridinyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-30-9 CAPLUS


CN     $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(2-pyridinyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)






RN 743433-32-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[6-(trifluoromethyl)-3-pyridinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-35-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3,5-dichlorophenyl)-3-[6-(trifluoromethyl)-3-pyridinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-38-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(3-(3,5-dichlorophenyl)-5-(5-methoxy-2-pyridinyl)-1H-pyrazol-1-yl)methyl]benzoyl]- (CA INDEX NAME)




RN 743433-40-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(5-[1,1'-biphenyl]-4-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl)methyl]benzoyl]- (CA INDEX NAME)




RN 743433-41-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[(3-(3,5-dichlorophenyl)-5-(4'-fluoro[1,1'-biphenyl]-4-yl)-1H-pyrazol-1-yl)methyl]benzoyl]- (CA INDEX NAME)




RN 743433-42-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-43-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4-(3-pyridinyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-45-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-(2,2-dimethyl-1-oxopropyl)-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-47-8 CAPLUS

CN β-Alanine, N-[4-[[5-(1-benzoyl-4-piperidinyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-49-0 CAPLUS

CN β-Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-51-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[1-(3,5-dichlorobenzoyl)-4-piperidinyl]-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-53-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-[1-(2,4-dichlorobenzoyl)-4-piperidinyl]-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-55-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-(phenylsulfonyl)-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-57-0 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-[[4-(trifluoromethyl)phenyl]sulfonyl]-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-59-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-[(3-methoxyphenyl)sulfonyl]-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-61-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[[4-[[2-carboxyethyl]amino]carbonyl]phenyl]methyl]-3-(3,5-dichlorophenyl)-1H-pyrazol-5-yl]-, 1-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 743433-62-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-64-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-67-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-([5-[1,1'-biphenyl]-3-yl]-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-68-3 CAPLUS


CN  $\beta$ -Alanine, N-[4-([3-(3,5-dichlorophenyl)-5-(3'-fluoro[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-69-4 CAPLUS


CN  $\beta$ -Alanine, N-[4-([5-(3-bromophenyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)






RN 743433-70-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(2'-methyl[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-71-8 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-[1,1'-biphenyl]-3-yl-5-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-74-1 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4'-methyl[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-75-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(3'-methoxy[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-76-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4'-methoxy[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-77-4 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[3-(3-pyridinyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-78-5 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(4'-cyano[1,1'-biphenyl]-3-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-79-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(3'-nitro[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-80-9 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[3-(3,5-dimethyl-4-isoxazolyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-81-0 CAPLUS

CN     $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4'-(hydroxymethyl)[1,1'-biphenyl]-3-yl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-82-1 CAPLUS

CN     $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4-(2-pyridinyl)phenyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-83-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-84-3 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(3'-cyano[1,1'-biphenyl]-4-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-85-4 CAPLUS

CN β-Alanine, N-[4-[[5-(3',4'-dichloro[1,1'-biphenyl]-4-yl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-86-5 CAPLUS

CN β-Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(3',5'-difluoro[1,1'-biphenyl]-4-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)




RN 743433-87-6 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-(2,2-dimethylpropyl)-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-89-8 CAPLUS


CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-(phenylmethyl)-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743433-91-2 CAPLUS




CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-[1-[[4-(trifluoromethoxy)phenyl]methyl]-4-piperidinyl]-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



RN 743436-71-7 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[3-(3,5-dichlorophenyl)-5-(4'-fluoro[1,1'-biphenyl]-3-yl)-1H-pyrazol-1-yl]methyl]benzoyl]- (CA INDEX NAME)



IT 743434-48-2F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of substituted pyrazoles as glucagon receptor antagonists for treating diabetes mellitus type 2)

RN 743434-48-2 CAPLUS

CN  $\beta$ -Alanine, N-[4-[[5-(4-bromophenyl)-3-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]methyl]benzoyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

